Stock Ratings / Health Care / INMD / insiders

CBLL (45) CNMD (65) CV (45) TMDX (62) ⌘ Pro Terminal →

InMode Ltd. (INMD) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$13.51 +1.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.51

InMode Ltd. (INMD) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $776.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INMD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, InMode Ltd. (NASDAQ: INMD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $13.51 (+1.05% 1D, market cap $776.6M). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, INMD ranks #200 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INMD compare to CBLL and CNMD in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), INMD carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of 78.5%, and ROIC of 17.7%. By comparison, CBLL (CeriBell Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B) and CNMD (CONMED Corporation) posts a C grade (65/100 RQD, P/E 28.9x, ROIC 7.8%, cap $1.36B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INMD?

▼

Per INMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001742692), InMode Ltd. generated $370.5M in revenue (-6.2% YoY), $0 in net income, and $84.3M in free cash flow against $766.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (79% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $13.51 (+0.00%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 22.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INMD)Realized 20D OHLCV Swing Band: ±3.2%

Deterministic 5-Pillar Attribution (58/100 Composite)

🔍 WHY INMD SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (28% of score)

Altman Z-Score 9.20 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+15/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 22.7% FCF Margin ($84.3M FCF) & 78.5% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$14.30-1.6% Next Q

Q2 (-2Q)

Grade C+$14.07-2.5% Next Q

Q3 (-1Q)

Grade C$13.72-1.5% Next Q

Current

Grade D+$13.51+0% Hist 90D α

Trajectory: B- (66) → D+ (58)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the INMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 58/100 (D+) score, INMD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 76.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($14.34) or 200D SMA ($14.33) invalidates the momentum regime and cuts Target Base ($13.51) toward Bear Floor ($10.54).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 58%NO 42%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

INMD Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (INMD)

No recent open-market Form 4 cluster sales or emergency dumps flagged on INMD. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INMD)

✓Walkthrough of INMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -5.59%▼ SUPPORT BREAKDOWN

2026-11-02O $13.37H $13.51L $13.37C $13.51VOL 370.6K

RES: $14.57SUP: $14.01SMA50: $14.34SMA200: $14.33

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INMD Butterfly Map → + Track INMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-8.3%/yr Implied 5Y Growth

vs. -6.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INMD)

Health Care Rank #200 of 1016 ⚔️ CBLL vs INMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INMD vs. CBLL, CNMD, CV, TMDX)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, InMode Ltd. (INMD) ranks #200 by composite RQD confidence (58/100, grade D+) and #390 by equity capitalization ($776.6M). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. CNMD currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with INMD at 58/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INMD ACTIVE InMode Ltd.	D+	58/100	—	78.5%	17.7%	+1.05%	$776.6M	Benchmark Subject
CBLL CeriBell Inc.	D	45/100	—	87.9%	-35.0%	+2.20%	$1.07B	/cbll-vs-inmd →
CNMD CONMED Corporation	C	65/100	28.9x	54.6%	7.8%	-0.09%	$1.36B	/cnmd-vs-inmd →
CV CapsoVision Inc.	D	45/100	—	52.9%	-35.0%	-1.70%	$369.2M	/cv-vs-inmd →
TMDX TransMedics Group Inc.	C	62/100	12.2x	59.9%	18.1%	+0.33%	$2.33B	/tmdx-vs-inmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001742692

In its most recent audited fiscal period (FY2025, filed 2025-12-31), InMode Ltd. (INMD) reported GAAP revenue of $370.5M (-6.2% vs. FY2024 revenue of $394.8M , and -24.7% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $85.3M, and free cash flow of $84.3M (-36.1% YoY). On the balance sheet, INMD closed FY2025 with $766.4M in total assets against $0 in total debt (Altman Z-Score: 9.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$370.5M	$0	$85.3M	$84.3M	$766.4M	—
FY2024 (FY)	2024-12-31	$394.8M	$0	$132.7M	$132.0M	$785.7M	—
FY2023 (FY)	2023-12-31	$492.0M	$197.9M	$176.8M	$176.8M	—	—

3. INMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does INMD compare to CBLL and CNMD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for INMD?

Where is INMD trading relative to its 50-day, 200-day, and 52-week technical levels?

INMD last traded at $13.51 (+1.05% on volume of 370,624 shares), positioning the stock -5.79% below its 50-day simple moving average ($14.34) and -5.72% below its 200-day simple moving average ($14.33). Across its 52-week range of $12.72 to $16.67, INMD sits at the 20.0% percentile with a 14-day RSI of 36.3 (NEUTRAL RANGE) and an implied next-earnings move of ±3.2% ($13.08 to $13.94).

INMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are INMD insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies INMD leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Direct Sub-Reports: INMD RQD Cockpit INMD 12M Forecast INMD Earnings & Move INMD Dividends & DRIP INMD Insiders & 13F INMD Whale Options INMD Profit Sankey INMD News & Why